MS4A1 and myeloid sarcoma: While ocrelizumab mainly targets peripheral CD20‐expressing B cells, a growing body of evidence suggests that meningeal inflammation containing CD20+ B cells and CNS‐compartmentalized B cells are associated with gray matter pathology and clinical progression in MS.25, 26